Overview

17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
All
Summary
Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. This phase I trial is studying the side effects and best dose of 17-N-allylamino-17-demethoxygeldanamycin in treating patients with advanced epithelial cancer, malignant lymphoma, or sarcoma
Phase:
Phase 1
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
National Cancer Institute (NCI)
Criteria
Inclusion Criteria:

- Histologically confirmed advanced epithelial cancer, malignant lymphoma, or sarcoma
for which no standard curative therapy exists

- Brain metastases allowed after definitive radiotherapy

- Performance status - ECOG 0-2

- Absolute neutrophil count at least 1,500/mm^3

- Platelet count at least 100,000/mm^3

- Bilirubin no greater than 1.5 mg/dL

- SGOT no greater than 2 times normal

- Creatinine no greater than 1.5 mg/dL

- Creatinine clearance at least 60 mL/min

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception for at least 1 week before, during,
and for at least 2 weeks after study completion

- No active infection

- No other serious concurrent condition

- No prior allergic reaction to egg products

- At least 4 weeks since prior biologic therapy (regional or systemic)

- At least 4 weeks since prior chemotherapy

- See Disease Characteristics

- At least 4 weeks since prior radiotherapy